Myasthenia Gravis Foundation of America Global MG Patient Registry

Conditions

• Myasthaenia Gravis
• Myasthenia
• Myasthenia Gravis
• Myasthenia Gravis Associated with Thymoma
• Myasthenia Gravis Crisis
• Myasthenia Gravis Exacerbations
• Myasthenia Gravis Generalised
• Myasthenia Gravis with Exacerbation (Disorder)
• Myasthenia Gravis, Adult Form
• Myasthenia Gravis, Generalized
• Myasthenia Gravis, MuSK
• Myasthenia Gravis, Ocular
• Myasthenia Gravis, Thymectomy

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Study Details

The goal of this observational study is to learn about the experiences of people living with Myasthenia Gravis (MG) in the United States. The main questions it aims to answer are: * How and when are people with MG diagnosed? * What are the most common symptoms associated with MG? * What treatments are being used to treat MG? * What are the impacts of MG on activities of daily living, employment and quality of life? * What are the experiences with exacerbation, hospitalization and healthcare access for people with MG? Participants will answer a survey to enroll in the study, and be invited to fill out an update survey twice a year.

Key Dates

Start date

Oct 12, 2013

Status verified

Sep 2024

Primary completion

Sep 19, 2029

Completion

Sep 19, 2029

Study Design

Enrollment

3,800 participants (estimated)

Arms

• Arm: Participants
  Those with Myasthenia Gravis

Primary Outcome Measure

Diagnosis of MG [ Time Frame: At enrollment ]

Central Contacts

• National Director, Patient Registry
  8005415454
  [email protected]

Locations (1)

Find similar trials in Westborough, MA

Related Studies

• A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
  PHASE3 · Recruiting · Janssen Research & Development, LLC · Paradise Valley, Arizona
• A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
  PHASE1 · Recruiting · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Birmingham, Alabama
• A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
  Recruiting · argenx · San Francisco, California
• Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
  PHASE3 · Recruiting · Cartesian Therapeutics · Tucson, Arizona